[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3534 followers Created: 2025-07-22 11:42:28 UTC TD Cowen🏁 $IDYA at a Buy rating. $PFE $GILD $DSNKY $AZN $RHHBY TD Cowen in its initiation report said, "IDEAYA's pipeline — with soon-to-be X clinical-stage programs — represents the best of targeted oncology and is led by a world-class team. The lead daro + criz combo should launch in 2026 in mUM, with a high likelihood of success in neoadjuvant. Near-term DLL3 ADC data are likely to be strong, and MAT2A efficacy should add to Trodelvy with NT data. We initiate at Buy given the very attractive EV." XXXXX engagements  **Related Topics** [$1b](/topic/$1b) [op](/topic/op) [rbc](/topic/rbc) [combo](/topic/combo) [$rhhby](/topic/$rhhby) [$dsnky](/topic/$dsnky) [$gild](/topic/$gild) [$idya](/topic/$idya) [Post Link](https://x.com/Quantumup1/status/1947623274436763862)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
quantumup @Quantumup1 on x 3534 followers
Created: 2025-07-22 11:42:28 UTC
TD Cowen🏁 $IDYA at a Buy rating. $PFE $GILD $DSNKY $AZN $RHHBY
TD Cowen in its initiation report said, "IDEAYA's pipeline — with soon-to-be X clinical-stage programs — represents the best of targeted oncology and is led by a world-class team.
The lead daro + criz combo should launch in 2026 in mUM, with a high likelihood of success in neoadjuvant.
Near-term DLL3 ADC data are likely to be strong, and MAT2A efficacy should add to Trodelvy with NT data. We initiate at Buy given the very attractive EV."
XXXXX engagements
